Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Empowering Physicians with Dr. Dana Corriel

Dana Corriel, MD, is a traditionally-trained physician who swapped clinical practice for digital entrepreneurship for innovation. After discovering she had a talent for design; unique content creating, during a short break from clinical medicine, she decided to “pay it forward” in her field of healthcare, and build an online platform that promoted doctors’ ideas; businesses. Corriel’s SoMeDocs was born. Today, she helps individuals AND companies alike to figure out next-steps in the online world. The ultimate mission of her company and work is to promote the autonomy of doctors everywhere, build a strong community of forward-thinking professionals, and provide well-needed networking in her field. To learn more about SoMeDocs, select the following link: doctorsonsocialmedia

#Corriel #SoMeDocs #physician #influencer #social #media

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!